Development of a Serum Biomarker Assay That Differentiates Tumor-associated MUC5AC (NPC-1C ANTIGEN) from Normal MUC5AC

Overview

Journal J Biomed Biotechnol

Specialty Biology

Date 2011 Jan 4

PMID 21197415

Citations 16

Authors

Janos Luka

Philip M Arlen

Andrew Bristol

Affiliations

Soon will be listed here.

Abstract

A serum ELISA using a monoclonal antibody that detects a MUC5AC-related antigen (NPC-1C antigen) expressed by pancreatic and colorectal cancer was developed. The NPC-1C antibody reacts with specific epitopes expressed by tumor-associated MUC5AC that does not appear on MUC5AC from normal tissues. Based on observations of a highly specific antibody, we tested the ELISA to differentiate serum from healthy blood donors compared to serum from patients with colorectal or pancreatic cancer. Additionally, patient tumor tissue was stained to examine the expression pattern of MUC5AC-related antigen in pancreatic and colorectal cancers. The results indicate the NPC-1C antibody ELISA distinguished serum of cancer patients from normal donors with very good sensitivity and specificity. Most patient's tumor biopsy exhibited NPC-1C antibody reactivity, indicating that tumor-associated MUC5AC antigen from tumor is shed into blood, where it can be detected by the NPC-1C antibody ELISA. This serum test provides a new tool to aid in the diagnosis of these cancers and immune monitoring of cancer treatment regimens.

Citing Articles

Current State of Knowledge on Blood and Tissue-Based Biomarkers for Opisthorchis viverrini-induced Cholangiocarcinoma: A Review of Prognostic, Predictive, and Diagnostic Markers.

Kafle A, Suttiprapa S Asian Pac J Cancer Prev. 2024; 25(1):25-41.

PMID: 38285765 PMC: 10911713. DOI: 10.31557/APJCP.2024.25.1.25.

Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence.

Manne A, Kasi A, Esnakula A, Paluri R Int J Mol Sci. 2023; 24(9).

PMID: 37175794 PMC: 10178741. DOI: 10.3390/ijms24098087.

Mucins as Potential Biomarkers for Early Detection of Cancer.

Gautam S, Khan P, Natarajan G, Atri P, Aithal A, Ganti A Cancers (Basel). 2023; 15(6).

PMID: 36980526 PMC: 10046558. DOI: 10.3390/cancers15061640.

Understanding the Clinical Significance of MUC5AC in Biliary Tract Cancers.

Benson K, Sheel A, Rahman S, Esnakula A, Manne A Cancers (Basel). 2023; 15(2).

PMID: 36672382 PMC: 9856870. DOI: 10.3390/cancers15020433.

Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.

Huffman B, Basu Mallick A, Horick N, Wang-Gillam A, Hosein P, Morse M JAMA Netw Open. 2023; 6(1):e2249720.

PMID: 36602796 PMC: 9856813. DOI: 10.1001/jamanetworkopen.2022.49720.

References

Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J . ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24(33):5313-27. DOI: 10.1200/JCO.2006.08.2644. View

Bara J, Gautier R, Mouradian P, Decaens C, Daher N . Oncofetal mucin M1 epitope family: characterization and expression during colonic carcinogenesis. Int J Cancer. 1991; 47(2):304-10. DOI: 10.1002/ijc.2910470222. View

Hollinshead A, Glew D, Bunnag B, Gold P, Herberman R . Skin-reactive soluble antigen from intestinal cancer-cell-membranes and relationship to carcinoembryonic antigens. Lancet. 1970; 1(7658):1191-5. DOI: 10.1016/s0140-6736(70)91784-8. View

Haab B, Porter A, Yue T, Li L, Scheiman J, Anderson M . Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann Surg. 2010; 251(5):937-45. PMC: 3713623. DOI: 10.1097/SLA.0b013e3181d7738d. View

Hollingsworth M, Swanson B . Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2003; 4(1):45-60. DOI: 10.1038/nrc1251. View

Han L, Pansare V, Al-Abbadi M, Husain M, Feng J . Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. Diagn Cytopathol. 2009; 38(5):333-6. DOI: 10.1002/dc.21202. View

Rex D, Johnson D, Anderson J, Schoenfeld P, Burke C, Inadomi J . American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009; 104(3):739-50. DOI: 10.1038/ajg.2009.104. View

DiMagno E, Reber H, Tempero M . AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology. 1999; 117(6):1464-84. DOI: 10.1016/s0016-5085(99)70298-2. View

Bara J, Gautier R, Le Pendu J, Oriol R . Immunochemical characterization of mucins. Polypeptide (M1) and polysaccharide (A and Leb) antigens. Biochem J. 1988; 254(1):185-93. PMC: 1135055. DOI: 10.1042/bj2540185. View

10.

Lamerz R . Role of tumour markers, cytogenetics. Ann Oncol. 1999; 10 Suppl 4:145-9. View

11.

Bara J, Gautier R, Daher N, Zaghouani H, Decaens C . Monoclonal antibodies against oncofetal mucin M1 antigens associated with precancerous colonic mucosae. Cancer Res. 1986; 46(8):3983-9. View

12.

Steinberg W . The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990; 85(4):350-5. View

13.

Nollet S, Forgue-Lafitte M, Kirkham P, Bara J . Mapping of two new epitopes on the apomucin encoded by MUC5AC gene: expression in normal GI tract and colon tumors. Int J Cancer. 2002; 99(3):336-43. DOI: 10.1002/ijc.10335. View

14.

Hollinshead A, Elias E, Arlen M, BUDA B, Mosley M, Scherrer J . Specific active immunotherapy in patients with adenocarcinoma of the colon utilizing tumor-associated antigens (TAA). A phase I clinical trial. Cancer. 1985; 56(3):480-9. DOI: 10.1002/1097-0142(19850801)56:3<480::aid-cncr2820560312>3.0.co;2-2. View

15.

Reis C, David L, Nielsen P, Clausen H, Mirgorodskaya K, Roepstorff P . Immunohistochemical study of MUC5AC expression in human gastric carcinomas using a novel monoclonal antibody. Int J Cancer. 1997; 74(1):112-21. DOI: 10.1002/(sici)1097-0215(19970220)74:1<112::aid-ijc19>3.0.co;2-h. View

16.

HOLLINSHEAD A, MCWRIGHT C, Alford TC GLEW D, Gold P, Herbeman R . Separation of skin reactive intestinal cancer antigen from the carcinoembryonic antigen of Gold. Science. 1972; 177(4052):887-9. DOI: 10.1126/science.177.4052.887. View